These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 17404078)

  • 1. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
    Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
    Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
    Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
    Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
    Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
    Power KA; Thompson LU
    Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
    Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
    Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients.
    Altundag O; Altundag K; Gunduz M
    Med Hypotheses; 2004; 63(4):684-7. PubMed ID: 15325017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of GATA3 expression in breast cancer: a 10-year follow-up study.
    Ciocca V; Daskalakis C; Ciocca RM; Ruiz-Orrico A; Palazzo JP
    Hum Pathol; 2009 Apr; 40(4):489-95. PubMed ID: 19084267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer.
    Borgquist S; Holm C; Stendahl M; Anagnostaki L; Landberg G; Jirström K
    J Clin Pathol; 2008 Feb; 61(2):197-203. PubMed ID: 18223096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of ERalpha and ERbeta in lobular carcinoma in situ.
    Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE
    Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.